Cytokinetics

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

R&D

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

News

Phase 3 fail prompts Cytokinetics to abandon ALS drug

There’s been a big disappointment for people with amyotrophic lateral sclerosis (ALS), after Cytokinetics said it was halting a trial of its resedemtiv candidate following

News

FDA rejects Cytokinetics’ heart failure drug

Firm will request a meeting with FDA, but may have to switch focus to folow-up drug aficamten.

News

FDA adcomm votes down Cytokinetics heart failure drug

An FDA advisory committee has voted against approval of Cytokinetics' cardiac myosin inhibitor omecamtiv mecarbil for heart failure, saying the data for the drug was not strong enough.

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

Cytokinetics rockets on positive heart drug trial

Health Innovators – Fady Malik and Steve Heitner

Phase 3 fail prompts Cytokinetics to abandon ALS drug

FDA rejects Cytokinetics’ heart failure drug

FDA adcomm votes down Cytokinetics heart failure drug

BMS bags FDA okay for cardiomyopathy drug mavacamten

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Cytokinetics

Editor's Picks